Stockscreener 앱 받기
1.53
25.18%
-0.515
시간 외 거래:
1.57
0.04
+2.61%
전일 마감가:
$2.045
열려 있는:
$1.78
하루 거래량:
4.83M
Relative Volume:
5.87
시가총액:
$10.74M
수익:
$5.75M
순이익/손실:
$-38.96M
주가수익비율:
-0.1227
EPS:
-12.47
순현금흐름:
$-32.63M
1주 성능:
-90.95%
1개월 성능:
-86.36%
6개월 성능:
-73.30%
1년 성능:
-73.16%
1일 변동 폭
$1.50
$1.95
1주일 범위
$1.10
$19.77
52주 변동 폭
$1.10
$20.60
칼라 파마슈티컬스 Stock (KALA) Company Profile
명칭
Kala Bio Inc
전화
781-996-5252
주소
1167 MASSACHUSETTS AVENUE, ARLINGTON, MA
KALA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KALA
Kala Bio Inc
|
1.53 | 14.36M | 5.75M | -38.96M | -32.63M | -12.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
칼라 파마슈티컬스 Stock (KALA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-30 | 다운그레이드 | Mizuho | Outperform → Neutral |
| 2025-09-29 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-09-29 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2025-09-08 | 개시 | Mizuho | Outperform |
| 2025-07-11 | 개시 | Ladenburg Thalmann | Buy |
| 2022-03-30 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2021-08-06 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-09-14 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-07-23 | 개시 | Northland Capital | Outperform |
| 2020-06-01 | 재개 | Oppenheimer | Outperform |
| 2020-05-27 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-09 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-12-17 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-03-14 | 개시 | Jefferies | Buy |
모두보기
칼라 파마슈티컬스 주식(KALA)의 최신 뉴스
KALA BIO, Inc. Securities Lawsuit Investigation - Claim Depot
Kala Bio Shares Fall After Downgrade From Mizuho - MarketScreener
A Heavy Trading Day Sends Biotech And Finance Stocks Reeling - Finimize
Kala Bio Faces Diminishing Options After Eye Drug Failure - insights.citeline.com
Mizuho Downgrades KALA BIO to Neutral From Outperform, Price Target is $1.50 - MarketScreener
Kala Bio tanks on Phase IIb KPI-012 miss - The Pharma Letter
KALA BIO (NASDAQ:KALA) Downgraded to Hold Rating by Lifesci Capital - MarketBeat
Forecasting KALA BIO Inc. price range with options dataJuly 2025 Movers & High Yield Equity Trading Tips - newser.com
Kala Bio Halts Eye Drug Development After Phase 2b Trial Failure - Medical Dialogues
Is KALA BIO Inc. meeting your algorithmic filter criteriaJuly 2025 Market Mood & Reliable Entry Point Alerts - newser.com
Electronic Arts, Kala Bio, Semtech - TradingView
KALA BIO (KALA) Price Target Increased by 23.00% to 31.36 - Nasdaq
KALA BIO (NASDAQ:KALA) Receives “Neutral” Rating from HC Wainwright - Defense World
Can KALA BIO Inc. stock surprise with earnings upsideJuly 2025 Closing Moves & Daily Profit Maximizing Trade Tips - newser.com
Is KALA BIO Inc. stock supported by strong cash flowsTrade Exit Summary & Reliable Price Breakout Alerts - newser.com
Quantitative breakdown of KALA BIO Inc. recent moveWeekly Trend Report & Safe Entry Point Identification - newser.com
Market Today: EA's Historic LBO and KALA BIO's Plunge - GuruFocus
KALA BIO Announces Topline Results from CHASE Phase 2b - GlobeNewswire
Biotech company to lay off half its workforce after eye drug fails trial - The Business Journals
KalaBio (KALA) Halts KPI-012 Development After Disappointing Tri - GuruFocus
HC Wainwright Downgrades KALA BIO to Neutral From Buy; Shares Plunge - MarketScreener
Crude Oil Falls Sharply; Carnival Posts Upbeat Earnings - Benzinga
Kala Bio stock plunges after failed Phase 2b trial for eye treatment - Investing.com
KALA Stock Falls Sharply After KPI-012 Clinical Trial Disappointment - GuruFocus
Arlington biotech slashes workforce in half after trial failure - The Business Journals
Why Is Eye Disease Focused Kala Bio Stock Plunging On Monday? - Benzinga
Kala Bio Stock Just Plunged 92% Today – Here’s What Happened - Asianet Newsable
KALA Bio (KALA) Stock Plummets 92% After Failed Trial - GuruFocus
Nasdaq Jumps 150 Points; US Pending Home Sales Rise - Benzinga
KALA Bio's KPI-012 Fails Phase 2b CHASE Study; Shares Plunge Over 90% In Pre-Market - Nasdaq
KALA's Phase 2b Trial of KPI-012 Falls Short of Key Milestones - GuruFocus
KALA BIO plunges 92% after phase 2 failure of eye condition drug - Seeking Alpha
Kala Pharmaceuticals Halts KPI-012 Development After Trial Failure - TipRanks
Kala Bio’s corneal treatment fails to meet primary endpoint in trial - Investing.com
Kala Bio plunges after scrapping development of lead drug - MarketScreener
Kala Bio announces topline results from Chase phase 2b clinical trial - MarketScreener
KALA BIO scraps development of eye disease drug after trial failure - MarketScreener
KALA BIO Announces Topline Results from CHASE Phase 2b Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) Did Not Meet Primary Endpoint - Yahoo Finance
Candlestick signals on KALA BIO Inc. stock today2025 Bull vs Bear & Momentum Based Trading Signals - newser.com
칼라 파마슈티컬스 (KALA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.36%
1.10%
자본화:
|
볼륨(24시간):